ClinicalTrials.gg
Active, not recruitingNCT04106349REPLICAUpdated Sep 30, 2026

Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)

An observational study in Advanced or Metastatic Renal Cell Carcinoma, sponsored by Ipsen. Active, not recruiting at 20 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Ipsen · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Carcinoma, Renal Cell by Ipsen — none open to participants now, 2 under way, none of them phase 3. Carcinoma, Renal Cell · Ipsen.

Planned enrollment
10th of 13
150 · median 252
Started
2020
with 4 others
Observational
13 of 16
none open now
Registered
10th of 16
by date

Among the 16 studies in Carcinoma, Renal Cell by Ipsen, this one is the 10th largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2020, is one of 13 observational ones, and was the 10th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 397 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

None of the 16 studies in Carcinoma, Renal Cell by Ipsen is open now. The open studies under Carcinoma, Renal Cell, anywhere →

Who these studies take

Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Carcinoma, Renal Cell by Ipsen as a file.
02

Study summary

The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)

03

Conditions studied

  • Advanced or Metastatic Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

advanced or metastatic renal cell carcinoma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged 18 years and older
  • Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or renal cell carcinoma
  • Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study
  • Provision of written

Exclusion criteria

Exclusion Criteria:

  • Participation in another interventional clinical study at the same time
  • Previous participation in this clinical study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1st line
  • 2nd line
  • later lines

This study also gives Nivolumab, Cabozantinib. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Treatment line

    Treatment line will be assessed at baseline. It is a percentage of patients receiving cabozantinib as 1st, 2nd or later lines of treatment or cabozantinib in monotherapy or in combination with nivolumab as 1st line of treatment.

    Time frame: Baseline

  2. Dose reductions and reasons

    Number of dose reductions and reason

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  3. Treatment interruptions and reason

    Number of treatment interruptions and reason

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  4. Treatment discontinuations and reason

    Number of patients with permanent discontinuation and reason

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  5. Alternative dose schedule

    Number of patients with schedules other than 1 pill at fixed dose/day for the total treatment period

    Time frame: From baseline until the end of study up to 9 months

  6. Mean number of any dose modification

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  7. Median number of any dose modification

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  8. Median time to any first dose modification

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  9. Median time to end of treatment

    Time frame: From baseline until the end of study up to 9 months

  10. Duration of treatment exposure

    Time frame: From baseline until the end of study up to 9 months

  11. Dose prescribed at initiation

    Number of patients with dose of 60 mg/day, 40 mg/day or 20 mg/day at baseline

    Time frame: Baseline

  12. Average daily dose

    Estimation of average daily dose received by subject during the treatment exposure

    Time frame: From baseline until the end of study up to 9 months

Secondary outcomes

  1. Change in Quality of Life score

    Changes in quality of life data by comparing changes in scores on Using the National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Kidney Symptom Index-19 (NFKSI-19). It describes the severity, interference, and frequency rates.

    Time frame: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop

  2. Progression Free Survival (PFS)

    Radiological progression using RECIST 1.1 or investigator assessed or according to local standard of care or death; PFS evaluated at least every 12 weeks under treatment with cabozantinib

    Time frame: From baseline until the end of study up to 9 months

  3. Objective Response Rate

    Percent of patients with partial and complete response during the treatment with cabozantinib

    Time frame: From baseline until the end of study up to 9 months

  4. Disease Control Rate

    Percent of patients with stable disease, partial and complete response during the treatment with cabozantinib

    Time frame: From baseline until the end of study up to 9 months

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Mar 2027, 84 months after the start.

Of 42 industry-sponsored observational studies under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 91. This study's planned 84 months is above that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2019
First posted
Sep 27, 2019
StartActual
Mar 3, 2020
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04106349
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Sep 27, 2019
Start date
Mar 3, 2020
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion